Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBITDA Multiple | 7,6x - 8,4x | 8,0x |
| Selected Fwd EBITDA Multiple | 4,7x - 5,2x | 5,0x |
| Fair Value | ₩10.557 - ₩11.830 | ₩11.193 |
| Upside | 32,3% - 48,2% | 40,3% |
| Benchmarks | Ticker | Full Ticker |
| Kukje Pharma Co., Ltd. | A002720 | KOSE:A002720 |
| Whan In Pharm Co.,Ltd. | A016580 | KOSE:A016580 |
| Kyung Dong Pharmaceutical Co., Ltd. | A011040 | KOSDAQ:A011040 |
| BCWORLD PHARM. Co., Ltd. | A200780 | KOSDAQ:A200780 |
| JW Lifescience Corporation | A234080 | KOSE:A234080 |
| Ahn-Gook Pharmaceutical Co., Ltd. | A001540 | KOSDAQ:A001540 |
| - | - | - |
| Select LTM EBITDA Multiple | |||||||
| Benchmark Companies | |||||||
| A002720 | A016580 | A011040 | A200780 | A234080 | A001540 | ||
| KOSE:A002720 | KOSE:A016580 | KOSDAQ:A011040 | KOSDAQ:A200780 | KOSE:A234080 | KOSDAQ:A001540 | ||
| Historical EBITDA Growth | |||||||
| 5Y CAGR | 2.4% | -0.1% | -23.9% | 28.2% | 4.5% | 18.0% | |
| 3Y CAGR | 53.4% | -5.5% | -29.3% | 36.2% | 7.4% | 61.3% | |
| Latest Twelve Months | 116.4% | -27.6% | 161.6% | -23.7% | 13.7% | 89.6% | |
| Historical EBITDA Profit Margin | |||||||
| 5 Year Average Margin | 5.0% | 17.0% | 6.1% | 9.3% | 24.0% | 4.5% | |
| Prior Fiscal Year | 1.6% | 16.0% | -11.7% | 18.4% | 22.4% | 4.3% | |
| Latest Fiscal Year | 6.3% | 11.5% | 4.1% | 12.3% | 23.2% | 5.3% | |
| Latest Twelve Months | 5.5% | 10.7% | 5.1% | 12.1% | 21.6% | 6.4% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 0.71x | 0.40x | 0.51x | 1.59x | 0.96x | 0.38x | |
| EV / LTM EBITDA | 12.9x | 3.7x | 10.1x | 13.1x | 4.4x | 6.0x | |
| EV / LTM EBIT | 20.2x | 5.6x | 20.3x | 91.6x | 6.4x | 11.4x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBITDA | 3.7x | 10.1x | 13.1x | ||||
| Historical EV / LTM EBITDA | 5.2x | 7.1x | 33.3x | ||||
| Selected EV / LTM EBITDA | 7.6x | 8.0x | 8.4x | ||||
| (x) LTM EBITDA | 18,029 | 18,029 | 18,029 | ||||
| (=) Implied Enterprise Value | 136,596 | 143,785 | 150,974 | ||||
| (-) Non-shareholder Claims * | (17,500) | (17,500) | (17,500) | ||||
| (=) Equity Value | 119,096 | 126,285 | 133,474 | ||||
| (/) Shares Outstanding | 11.4 | 11.4 | 11.4 | ||||
| Implied Value Range | 10,478.83 | 11,111.39 | 11,743.95 | ||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 10,478.83 | 11,111.39 | 11,743.95 | 7,980.00 | |||
| Upside / (Downside) | 31.3% | 39.2% | 47.2% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A002720 | A016580 | A011040 | A200780 | A234080 | A001540 | |
| Enterprise Value | 113,497 | 102,500 | 99,906 | 117,882 | 231,413 | 108,196 | |
| (+) Cash & Short Term Investments | 9,932 | 54,601 | 32,582 | 7,143 | 26,465 | 31,749 | |
| (+) Investments & Other | 4,603 | 31,625 | 68,323 | 2,999 | 2,062 | 27,619 | |
| (-) Debt | (29,467) | (788) | (36,205) | (86,917) | (65,299) | (77,879) | |
| (-) Other Liabilities | (11) | 0 | (261) | 479 | 0 | 1,012 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 98,555 | 187,938 | 164,345 | 41,585 | 194,641 | 90,696 | |
| (/) Shares Outstanding | 20.4 | 15.3 | 26.9 | 9.3 | 15.5 | 11.4 | |
| Implied Stock Price | 4,840.00 | 12,310.00 | 6,100.00 | 4,480.00 | 12,570.00 | 7,980.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 4,840.00 | 12,310.00 | 6,100.00 | 4,480.00 | 12,570.00 | 7,980.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |